ArticleMMWR. Morbidity and mortality weekly report2026
Increase in Travel-Associated and Locally Acquired Dengue Cases - United States, 2024.
Article in MMWR. Morbidity and mortality weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unresolved questions in pediatric dengue: from disease mechanisms to prevention.Current opinion in infectious diseases · 2026Review
- Dengue Vaccines in a Changing Epidemiological Landscape: Current Evidence, Unresolved Challenges, and Public Health Considerations.Vaccines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is a mosquitoborne viral disease that can cause mild to severe illness and death. During 2010-2023, an average of 828 dengue cases (range = 202-2,055) were reported annually to ArboNET, the national arboviral surveillance system for the 50 U.S. states and the District of Columbia. During 2024, a record 3,798 dengue cases were reported, representing a 359% increase above the 2010-2023 annual average. Among these 3,798 cases, 97.2% were associated with travel outside the reporting jurisdiction during the 2 weeks preceding symptom onset; the remaining 2.8% were locally acquired. The number of dengue cases peaked during July-September (accounting for 41.6% of total annual cases), with the highest percentage (21.8%) of cases occurring among persons aged 50-59 years. Among travel-associated cases, acquisition occurred primarily in the Caribbean (including Puerto Rico and the U.S. Virgin Islands) (34.1%), North America (Mexico and the United States) (24.3%), and Central America (15.6%); Hispanic or Latino persons accounted for 57.5% of all cases. Among all patients, 36.1% required hospitalization, 2.8% of cases were severe, and six (0.2%) patients died. Among 1,204 patients with known dengue virus (DENV) serotype, DENV-3 was the most commonly reported (54.8%) among the four DENV serotypes. These findings underscore the urgent need for enhanced prevention strategies, clinical awareness, and tailored public health messaging for travelers to areas where dengue is endemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.